04 September 2015

Scientists turn to aspirin to turbo-charge cancer immunotherapy

Giving aspirin may help to boost the effectiveness of immunotherapy treatment in cancer patients


Giving cheap aspirin to cancer patients may turbo-charge the effectiveness of expensive new medicines that help their immune systems fight tumors, experiments on mice suggest. Immunotherapy promises to revolutionise cancer care by offering a better, longer-lasting response with fewer adverse side effects than conventional treatment, but the new drugs do not work well in all cases. One reason is that cancer cells often produce large amounts of the molecule prostaglandin E2 (PGE2), which turns down the immune system's normal attack response to tumour cells, according to scientists at London's new Francis Crick Institute.

Aspirin blocks PGE2 production and the researchers found that adding it to an immunotherapy treatment called anti-PD-1 substantially slowed the growth of bowel and melanoma cancers in mice when compared with treatment by immunotherapy alone. There is already some evidence that the findings in mice will apply to human tissue but there is still a long way to go before this is proven. Still, the research adds to aspirin's reputation as a "wonder drug." First synthesised by a chemist at Bayer more than a century ago, the medicine is already used to prevent heart attacks and has previously been reported to reduce the risk of bowel and other cancers.

Caetano Reis e Sousa, senior group leader at the London institute, hopes that adding aspirin or other so-called COX inhibitor drugs will one day make a big difference to the benefits the patients get from immunotherapy. "What we would like to do next is set up a clinical trial," he told Reuters. "We will need to persuade a company to sponsor that and we have had some preliminary conversations."Merck and Bristol-Myers Squibb both have recently approved anti-PD-1 drugs, while competing anti-PD-L1 medicines are in development at rival companies including Roche and AstraZeneca.

In the experiments on mice, details of which were published in the journal Cell on Thursday, researchers used a mouse-specific anti-PD-1, but Reis e Sousa said he expected the aspirin effect to be similar with human medicines blocking PD-1, PD-L1 and another class of drugs targeting CTLA-4. With future immunotherapy use widely expected to involve multi-drug combinations, adding aspirin to the mix would be one way to help keep a lid on soaring costs.

Read more:

Food as medicine? 

Children with cancer often use alternative medicine 

Asprin to treat cancer? 



Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst and Head of Advocacy Magdalene Seguin. For more information, visit

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules